Crescent Biopharma (CBIO) Other Non-Current Liabilities (2020 - 2021)
Crescent Biopharma (CBIO) posted quarterly Other Non-Current Liabilities of $538587.0 for Q3 2021, up 199.02% year-over-year from $180117.0 in Q3 2020, and up 31.9% quarter-over-quarter from $408323.0 in Q2 2021.
Crescent Biopharma (CBIO) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Crescent Biopharma (CBIO) has reported Other Non-Current Liabilities for 2 consecutive years, with $538587.0 the latest figure, recorded in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 538,587.00 |
| Jun 30, 2021 | 408,323.00 |
| Mar 31, 2021 | 373,911.00 |
| Sep 30, 2020 | 180,117.00 |
| Mar 31, 2020 | 393,273.00 |